A doctor administers a vaccine to a patient. (Adobe Stock Photo)
February 28, 2026 09:43 AM GMT+03:00
Europe’s medicines regulator has relocated to clear a new dual-purpose vaccine, as the human medicines committee of the European Medicines Agency recommconcludeed approval of a combined COVID-19 and seasonal influenza shot developed by Moderna for adults aged 50 years and older.
Trial results reveal strong dual protection
The vaccine, known as mCombriax, is an mRNA-based formulation designed to protect against both SARS-CoV-2 and circulating influenza strains in a single injection.
According to European health authorities, clinical studies demonstrated that immune responses generated by the combined vaccine were comparable to those observed when separate COVID-19 and influenza vaccines were administered.
Regulators reported that the safety profile of the vaccine was consistent with existing immunizations, with commonly observed side effects including injection site pain, fatigue, and muscle discomfort, generally classified as mild to moderate.
More to Read
Final EU approval process underway
The recommconcludeation will now be reviewed by the European Commission, which is responsible for issuing a final authorization decision. Such approvals are typically adopted following a positive scientific opinion from the EMA.
If authorized, the vaccine would become available across member states of the European Union as well as countries within the European Economic Area.
February 28, 2026 09:43 AM GMT+03:00
Leave a Reply